Quantcast

Latest Renal cell carcinoma Stories

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-09-24 04:21:41

WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including Stivarga(®) (regorafenib) tablets, NEXAVAR(®) (sorafenib) tablets and Xofigo(®) (radium Ra 223 dichloride) injection, will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress taking place September 26 - 30 in Madrid, Spain. "Bayer's presence at this global medical congress demonstrates our commitment to research...

2014-09-01 23:00:51

MarketOptimizer.org adds “EpiCast Report Renal Cell Carcinoma - Epidemiology Forecast to 2023” to its store. This forecast is supported by age- and sex-specific data for the incidence. Dallas, Texas (PRWEB) September 02, 2014 Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. The condition is asymptomatic in its...

2014-07-25 04:21:37

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR(®) (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-07 08:22:14

-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase III DECISION trial TORONTO, July 7, 2014 /CNW/ - Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally...

Treasure Trove Of Genes Key To Kidney Cancer Revealed By Researchers
2014-07-01 03:24:43

[ Watch The Video: Mayo Clinic Researchers Uncovered 31 Genes Key To Development Of Kidney Cancer ] Mayo Clinic A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. Eight of these genes had not been previously linked to kidney cancer, and six other genes were never known to be involved in any...

2014-06-24 14:03:33

Mayo Clinic A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. Their study, published in Cancer Research, reveals that the gene NPTX2, plays an essential role in this cancer type, which is resistant to common chemotherapy and has a five-year overall survival rate of less than 10 percent in patients with metastatic disease....

2014-06-16 12:29:10

CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- Boston Biomedical, a company focused on the research and development of novel cancer therapeutics targeting cancer stem cells (CSC), today provided a summary of the clinical data presented at the 2014 American Society of Clinical Oncology (ASCO) 50(th) annual meeting, held from May 30 to June 3, 2014, in Chicago, IL. Clinical data were presented for BBI608 and BBI503, novel agents targeting cancer stem cells that have been developed by...

2014-06-03 08:32:24

Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX(®) test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related